{"id":11402,"date":"2023-01-16T09:58:58","date_gmt":"2023-01-16T08:58:58","guid":{"rendered":"https:\/\/ggba.swiss\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/"},"modified":"2023-07-04T13:44:11","modified_gmt":"2023-07-04T11:44:11","slug":"la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/","title":{"rendered":"La start-up genevoise STALICLA signe un accord de licence exclusif avec Novartis"},"content":{"rendered":"\n<p><a href=\"https:\/\/stalicla.com\/\" target=\"_blank\" rel=\"noopener\">STALICLA<\/a> est une soci\u00e9t\u00e9 biotechnologique de neuroscience mol\u00e9culaire de pr\u00e9cision au stade clinique, qui d\u00e9veloppe la premi\u00e8re plateforme de m\u00e9decine de pr\u00e9cision (DEPI) pour les patients atteints de troubles du d\u00e9veloppement neurologique (TND). La DEPI, qui a fait ses preuves dans d&rsquo;autres programmes de neurod\u00e9veloppement, a permis d&rsquo;identifier deux sous-groupes distincts de patients atteints de troubles du spectre autistique et leurs traitements sur mesure STP1 et STP2. Les deux m\u00e9dicaments devraient entrer en phase 2 des essais cliniques en 2023. STP1 et STP2 repr\u00e9sentent un march\u00e9 potentiel de plusieurs milliards de dollars.<\/p>\n<p>Bas\u00e9e sur le <a href=\"https:\/\/www.campusbiotech.ch\/\" target=\"_blank\" rel=\"noopener\">Campus Biotech<\/a> \u00e0 Gen\u00e8ve, cette entreprise de pr\u00e8s de six ans a conclu un accord de licence exclusif avec <a href=\"https:\/\/www.novartis.com\/\" target=\"_blank\" rel=\"noopener\">Novartis<\/a> pour faire progresser un m\u00e9dicament candidat de stade avanc\u00e9, le mavoglurant (AFQ056), un antagoniste s\u00e9lectif non allost\u00e9rique du r\u00e9cepteur 5 du glutamate m\u00e9tabotropique (mGluR5). Le mGluR5 a \u00e9t\u00e9 li\u00e9 aux troubles de l&rsquo;humeur, \u00e0 la d\u00e9pendance et \u00e0 des formes rares et courantes d&rsquo;autisme.<\/p>\n<p>Le mavoglurant a d\u00e9j\u00e0 \u00e9t\u00e9 test\u00e9 sur plus de 1&rsquo;800 patients et a d\u00e9montr\u00e9 un bon profil de s\u00e9curit\u00e9 et de tol\u00e9rance. Suite aux r\u00e9sultats tr\u00e8s prometteurs d&rsquo;une \u00e9tude de phase 2 men\u00e9e avec le mavoglurant dans le trouble de l&rsquo;usage de la coca\u00efne (TUC), STALICLA se pr\u00e9pare maintenant \u00e0 faire passer le mavoglurant en phase 3 de d\u00e9veloppement pour le traitement du TUC.<\/p>\n<p>Parall\u00e8lement, STALICLA s&rsquo;appuiera sur sa plateforme de d\u00e9veloppement de m\u00e9dicaments en neurobiologie de pr\u00e9cision (DEPI) pour d\u00e9tecter des sous-groupes de patients \u00e0 haut taux de r\u00e9ponse souffrant de troubles neurod\u00e9veloppementaux rares et courants, pour lesquels le mavoglurant peut constituer un traitement efficace, comme l&rsquo;ont montr\u00e9 des \u00e9tudes cliniques ant\u00e9rieures.<\/p>\n<p>Le potentiel commercial des seules indications TUC et TND pourrait d\u00e9passer les EUR 2 milliards au niveau mondial.<\/p>\n<h4>Une preuve de la force de la plateforme de m\u00e9decine neurobiologique de STALICLA<\/h4>\n<p>\u00ab\u00a0Cet accord avec Novartis t\u00e9moigne de la force de notre plateforme de m\u00e9decine neurobiologique de pr\u00e9cision. Nous sommes ravis de cette transaction qui nous permettra de poursuivre le d\u00e9veloppement du mavoglurant et de le proposer aux personnes qui en ont besoin\u00a0\u00bb, a d\u00e9clar\u00e9 Lynn Durham, CEO et fondatrice de STALICLA.<\/p>\n<p>Selon les termes de l&rsquo;accord, STALICLA a acquis les droits mondiaux sur le mavoglurant pour les troubles li\u00e9s \u00e0 la consommation de substances, les troubles du d\u00e9veloppement neurologique et d&rsquo;autres indications, en \u00e9change d&rsquo;un paiement initial et d&rsquo;une participation au capital, ainsi que d&rsquo;\u00e9tapes de d\u00e9veloppement et de commercialisation d&rsquo;un montant maximal de USD 270 millions, plus des commissions sur les ventes.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>STALICLA a acquis les droits mondiaux sur le candidat-m\u00e9dicament mavoglurant de Novartis, un traitement pour les troubles li\u00e9s \u00e0 la toxicomanie et les troubles du d\u00e9veloppement neurologique, avec un paiement initial non divulgu\u00e9, une participation au capital et jusqu&rsquo;\u00e0 USD 270 millions de paiements \u00e9chelonn\u00e9s.<\/p>\n","protected":false},"author":3,"featured_media":11403,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1022,1068,1069,1072],"class_list":["post-11402","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr","tag-personalized-medicine-fr","tag-pharma-fr","tag-rd-fr"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La start-up genevoise STALICLA signe un accord de licence exclusif avec Novartis - Greater Geneva Bern area<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La start-up genevoise STALICLA signe un accord de licence exclusif avec Novartis - Greater Geneva Bern area\" \/>\n<meta property=\"og:description\" content=\"STALICLA a acquis les droits mondiaux sur le candidat-m\u00e9dicament mavoglurant de Novartis, un traitement pour les troubles li\u00e9s \u00e0 la toxicomanie et les troubles du d\u00e9veloppement neurologique, avec un paiement initial non divulgu\u00e9, une participation au capital et jusqu&#039;\u00e0 USD 270 millions de paiements \u00e9chelonn\u00e9s.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-16T08:58:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-04T11:44:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"630\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"mathieu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"mathieu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/\"},\"author\":{\"name\":\"mathieu\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"headline\":\"La start-up genevoise STALICLA signe un accord de licence exclusif avec Novartis\",\"datePublished\":\"2023-01-16T08:58:58+00:00\",\"dateModified\":\"2023-07-04T11:44:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/\"},\"wordCount\":475,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-2.png\",\"keywords\":[\"Biotech\",\"Personalized Medicine\",\"Pharma\",\"R&amp;D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/\",\"name\":\"La start-up genevoise STALICLA signe un accord de licence exclusif avec Novartis - Greater Geneva Bern area\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-2.png\",\"datePublished\":\"2023-01-16T08:58:58+00:00\",\"dateModified\":\"2023-07-04T11:44:11+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-2.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-2.png\",\"width\":630,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La start-up genevoise STALICLA signe un accord de licence exclusif avec Novartis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\",\"name\":\"mathieu\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/mathieu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La start-up genevoise STALICLA signe un accord de licence exclusif avec Novartis - Greater Geneva Bern area","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/","og_locale":"fr_FR","og_type":"article","og_title":"La start-up genevoise STALICLA signe un accord de licence exclusif avec Novartis - Greater Geneva Bern area","og_description":"STALICLA a acquis les droits mondiaux sur le candidat-m\u00e9dicament mavoglurant de Novartis, un traitement pour les troubles li\u00e9s \u00e0 la toxicomanie et les troubles du d\u00e9veloppement neurologique, avec un paiement initial non divulgu\u00e9, une participation au capital et jusqu'\u00e0 USD 270 millions de paiements \u00e9chelonn\u00e9s.","og_url":"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-01-16T08:58:58+00:00","article_modified_time":"2023-07-04T11:44:11+00:00","og_image":[{"width":630,"height":380,"url":"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-2.png","type":"image\/png"}],"author":"mathieu","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"mathieu","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/"},"author":{"name":"mathieu","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"headline":"La start-up genevoise STALICLA signe un accord de licence exclusif avec Novartis","datePublished":"2023-01-16T08:58:58+00:00","dateModified":"2023-07-04T11:44:11+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/"},"wordCount":475,"image":{"@id":"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-2.png","keywords":["Biotech","Personalized Medicine","Pharma","R&amp;D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/","url":"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/","name":"La start-up genevoise STALICLA signe un accord de licence exclusif avec Novartis - Greater Geneva Bern area","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-2.png","datePublished":"2023-01-16T08:58:58+00:00","dateModified":"2023-07-04T11:44:11+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-2.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-2.png","width":630,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/la-start-up-genevoise-stalicla-signe-un-accord-de-licence-exclusif-avec-novartis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"La start-up genevoise STALICLA signe un accord de licence exclusif avec Novartis"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab","name":"mathieu","url":"https:\/\/ggba.swiss\/fr\/author\/mathieu\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/11402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=11402"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/11402\/revisions"}],"predecessor-version":[{"id":18303,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/11402\/revisions\/18303"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/11403"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=11402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=11402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=11402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}